MediGene AG Share Price Xetra
Equities
DE0005020903
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
06-27 | Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness | CI |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
Sales 2024 * | 10.6M 11.38M 900M | Sales 2025 * | 6.95M 7.46M 590M | Capitalization | 32.87M 35.3M 2.79B |
---|---|---|---|---|---|
Net income 2024 * | -11M -11.81M -934M | Net income 2025 * | -17M -18.26M -1.44B | EV / Sales 2024 * | 4.7 x |
Net Debt 2024 * | 17M 18.26M 1.44B | Net Debt 2025 * | 14M 15.03M 1.19B | EV / Sales 2025 * | 6.74 x |
P/E ratio 2024 * |
-3.01
x | P/E ratio 2025 * |
-1.99
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.05% |
Latest transcript on MediGene AG
Managers | Title | Age | Since |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 24/07/22 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/14 |
Pamela Keck
IRC | Investor Relations Contact | - | 31/01/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 11/08/16 | |
Frank Mathias
BRD | Director/Board Member | 62 | 14/05/18 |
Anthony Man
BRD | Director/Board Member | 68 | 15/12/20 |
1st Jan change | Capi. | |
---|---|---|
+15.82% | 121B | |
+20.35% | 113B | |
+17.47% | 26.02B | |
-25.31% | 19.39B | |
-19.51% | 15.91B | |
-19.67% | 15.09B | |
-46.87% | 15.06B | |
+62.55% | 14.93B | |
+6.34% | 13.85B |